Los Angeles Capital Management
EWTX icon

Los Angeles Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Los Angeles Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35K Sell
230
-5,370
-96% -$185K ﹤0.01% 1984
2026
Q1 		$176K Sell
5,600
-2,577
-32% -$74.3K ﹤0.01% 1179
2025
Q4 		$153K Buy
+8,177
New +$164K ﹤0.01% 1314

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Los Angeles Capital Management's EWTX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 96% in Q2 2026, selling an estimated $185K and leaving 230 shares worth $9.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Los Angeles Capital Management first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $176K in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Los Angeles Capital Management held 230 shares of Edgewise Therapeutics worth $9.35K as of Q2 2026.
  • Los Angeles Capital Management sold 5,370 Edgewise Therapeutics shares in Q2 2026, an estimated $185K.
  • Edgewise Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1984 holding.
  • Los Angeles Capital Management first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Los Angeles Capital Management's Edgewise Therapeutics position peaked at $176K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.